
    
      The following antiretroviral drugs are followed by the Antiretroviral Pregnancy Registry
      (APR, Registry) to detect any major teratogenic effect when administered to pregnant women:
      abacavir (ZIAGEN®, ABC), abacavir/lamivudine combination (EPZICOM®, KIVEXA®, EPZ),
      abacavir/lamivudine/zidovudine combination (TRIZIVIR®, TZV), abacavir/dolutegravir/lamivudine
      combination (TRIUMEQ®, TRI), adefovir dipivoxil (HEPSERA®, ADV), amprenavir (AGENERASE®,
      APV), atazanavir (REYATAZ®, ATV), atazanavir/cobicistat combination (EVOTAZ®, EVO),
      bictegravir/emtriciabine/tenofovir alafenamide (BIKTARVY®, B/F/TAF), cobicistat (TYBOST®,
      COBI), darunavir (PREZISTA®, DRV), darunavir/cobicistat combination (PREZCOBIX™, REZOLSTA™,
      PCX), delavirdine mesylate (RESCRIPTOR®, DLV), didanosine (VIDEX®, VIDEX® EC, ddI),
      dolutegravir (TIVICAY®, DTG), dolutegravir+lamivudine+tenofovir disoproxil fumarate
      (acriptega/teladomyl/tendola, TLD), dolutegravir/rilpivirine (JULUCA™, DTG/RPV), doravirine
      (pifeltro™, PIF), doravirine+lamivudine+tenofovir disoproxil fumarate (delstrigo™, DEL),
      emtricitabine/ tenofovir alafenamide (DESCOVY®,DVY) efavirenz (SUSTIVA®, STOCRIN®, EFV),
      efavirenz/emtricitabine/ tenofovir disoproxil combination (ATRIPLA® ATR),
      efavirenz/lamivudine/tenofovir disoproxil fumarate (SYMFI LO™, EFV/3TC/TDF), elvitegravir
      (VITEKTA®, EVG), elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide combination
      (GENVOYA®, GEN), elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
      combination (STRIBILD®, STB), emtricitabine (EMTRIVA®, FTC), enfuvirtide (FUZEON®, T-20),
      entecavir (BARACLUDE®, ETV), etravirine (INTELENCE®, ETR), fosamprenavir calcium (LEXIVA®,
      FOS), indinavir (CRIXIVAN®, IDV), lamivudine (EPIVIR®, 3TC), lamivudine/raltegravir
      combination (DUTREBIS™, DUT), lamivudine/tenofovir disoproxil fumarate (CIMDUO™, 3TC/TDF),
      lamivudine/zidovudine combination (COMBIVIR®, CBV), lopinavir/ritonavir combination
      (KALETRA®, ALUVIA®, LPV/r), maraviroc (SELZENTRY®, CELSENTRI®, MVC), nelfinavir (VIRACEPT®,
      NFV), nevirapine (VIRAMUNE®, VIRAMUNE® XR™, NVP), raltegravir (ISENTRESS®, RAL), rilpivirine
      (EDURANT®, RPV), rilpivirine/emtricitabine/tenofovir alafenamide (ODEFSEY®,ODE)
      rilpivirine/emtricitabine/tenofovir disoproxil combination (COMPLERA®, CPA; EVIPLERA®, EPA),
      ritonavir (NORVIR®, RTV), saquinavir (FORTOVASE®, SQV-SGC), saquinavir mesylate (INVIRASE®,
      SQV-HGC), stavudine (ZERIT®, d4T), telbivudine (SEBIVO®, TYZEKA®, LdT), tenofovir alafenamide
      (VEMLIDY®, TAF), tenofovir disoproxil fumarate (VIREAD®, TDF), tenofovir disoproxil fumarate
      /emtricitabine (TRUVADA®, TVD), tipranavir (APTIVUS®, TPV), zalcitabine (HIVID®, ddC), and
      zidovudine (RETROVIR®, ZDV).

      Zidovudine is indicated for use in the second and third trimesters of pregnancy to reduce the
      risk of maternal-fetal HIV transmission. There are also several other completed and ongoing
      studies in maternal-fetal transmission with other therapies. However, the safety of prenatal
      zidovudine or any other antiretroviral therapy exposure to the fetus has not been
      established.
    
  